

PCR-/NAT *Helicobacter pylori*
(RV 533) November 2017



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1725331	++	61/71	<i>Helicobacter pylori</i> (~ 5x10 ⁵ CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)
1725332	∅	62	<i>Helicobacter mustelae</i> (~ 5x10 ⁵ CFU/mL)
1725333	+++	61/72	<i>Helicobacter pylori</i> (~ 5x10 ⁶ CFU/mL) Clarithromycin susceptible (wildtype 23S rDNA sequence)
1725334	∅	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

n = 38	Probennummer (Sample no.)				Inhibition				
Befund Result	1725331	1725332	1725333	1725334		1725331	1725332	1725333	1725334
Positiv	38 ¹⁾	2	37 ¹⁾	2	n.d.	0	0	0	0
Negativ	0	36	1	36	nein no	38	38	38	38
Fraglich Questionable	0	0	0	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.
Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
Hain GenoType Helico [20] (n = 18)	35	35 / 36	97	34	34 / 36	94
Ingenetix ClariRes [21] (n = 3)	6	6 / 6	100	6	6 / 6	100
r-Biopharm RIDAGENE [22] (n = 5)	10	10 / 10	100	9	9 / 10	90
Commercial assay [27] (n = 2)	4	4 / 4	100	3	3 / 4	75
In house PCR assay [28] (n = 13)	26	26 / 26	100	26	26 / 26	100

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.
 Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants

Comments: ¹⁾ Thirty-six of the 38 participants reported results for molecular Clarithromycin-susceptibility testing. With the exception of 1 laboratory, all reported results were correct.